Prozac for binge eating reviews

Prozac monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder.It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome see warnings AND precautions.Johns Wort see contraindications, warnings AND precautions, and drug interactions.Whether any of the symptoms described for clinical worsening and suicide risk represent such a conversion is unknown.NES and sred are quite different.Prozac for Dogs and Cats Prozac is sometimes prescribed for dogs or cats under the care of a veterinarian.The benefits and risks of Prozac in the third trimester of pregnancy should be very closely evaluated.No adverse effects on the infant were reported.Consider ECG assessment and periodic ECG monitoring if initiating treatment with prozac in patients with risk factors for QT prolongation and ventricular arrhythmia.Pregnancy Pregnancy Category C prozac should be used during pregnancy only if the potential benefit justifies the potential risk to jak wywróżyć numery lotto the fetus.Although these reactions are rare, they may be serious, involving the lung, kidney, casino online spiele kostenlos ohne anmeldung nicht or liver.Other problems to be considered Binge-eating disorder (BED) BED is characterized by frequent and recurrent binge eating episodes without consistent compensatory behaviors.Pimozide and thioridazine are contraindicated for use with prozac.Prozac and Weight Gain Weight gain is a side effect of many antidepressants, including Prozac.DSM-5 describes that compensatory behaviors may include purging and/or nonpurging behaviors (see below in contrast to earlier DSM editions, DSM-5 no longer maintains specific purging and nonpurging subtypes.If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered.Prozac should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus see Use In Specific Populations.The risk differences (drug versus placebo however, were relatively stable within age strata and across indications.Cognitive problems involving thinking, concentration, attention, memory or speech might occur.A lower or less frequent dose of fluoxetine should be used in patients with cirrhosis.All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg.These features are consistent with either a direct toxic effect of ssris and snris or, possibly, a drug discontinuation syndrome.In US placebo-controlled clinical trials for Bulimia Nervosa, insomnia was reported in 33 of patients treated with prozac 60 mg, and 13 of patients treated with placebo.DSM-5 diagnostic criteria require episodes of binge eating that occur at least once weekly for 3 months.Pediatric Use Use Of prozac In Children The efficacy of prozac for the treatment of Major Depressive Disorder was demonstrated in two 8-to 9-week placebo-controlled clinical trials with 315 pediatric outpatients ages 8 to 18 see Clinical Studies.In US placebo-controlled clinical trials for Major Depressive Disorder, 11 of patients treated with prozac and 2 of patients treated with placebo reported anorexia ( decreased appetite ).The drug can cause sleepiness and may worsen your ability to make decisions, think clearly, or react quickly.However, because fluoxetine crosses the placenta and because of the possibility that fluoxetine may have adverse effects on the newborn, fluoxetine should be used during labor and delivery only if the potential benefit justifies the potential risk to the fetus.In US placebo-controlled clinical trials for OCD, 17 of patients treated with prozac and 10 of patients treated with placebo reported anorexia (decreased appetite).

Patients treated with prozac 60 mg on average lost.45 kg compared with a gain.16 kg by patients treated with placebo in the 16-week double-blind trial.Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older.There was no evidence of developmental neurotoxicity in the surviving offspring of rats treated with 12 mg/kg/day during gestation.